Celebrating 10 Years of NCER-PD
| TIME | PROGRAM 8h15-18h30 |
| 8:15 – 8:45 | Registration & Welcome coffee |
| 8:45– 9:00 | Welcome address by organizers: Prof. Rejko Krüger, LIH, LCSB, CHL Minister Dr Stéphanie Obertin, Minister for Research and Higher Education in Luxembourg Dr. Frank Glod, Deputy CEO, Luxembourg Institute at Health Prof. Simone Niclou, Vice-Rector for Research, University of Luxembourg |
| 9:00 – 9:40 | Keynote Speaker: Prof. Roger Barker, The current status and future of dopamine cell-based therapies for Parkinson’s, University of Cambridge, UK |
| Session 1: Clinical, Molecular and Pathological Stratification of PD | Chair: Prof. Dr. Nico Diederich, Centre Hospitalier de Luxembourg |
| 9:40 – 10:05 | Prof. Kathrin Brockmann, Clinical and molecular stratification in preparation of clinical trials. University Tübingen, DE |
| 10:05 – 10:30 | Prof. Dr. Per Borghammer, Brain first and body first PD – evidence and implications, Aarhus University Hospital, DK |
| 10:30 – 10:55 | Prof. Enza Maria Valente, Multimodal stratification of GBA-PD, University of Pavia, IT |
| 10:55 – 11:25 | Coffee break with exhibition and poster session |
| Session 2: Patient-derived cellular modelling of neurodegeneration | Chair: Prof. Dr. Anne Grünewald, University of Luxembourg |
| 11:25 – 11:50 | Prof. Céline Galvagnion, Disruptions in lipid levels associated with Parkinson’s Disease and alpha-synuclein pathology. University of Copenhagen, DK |
| 11:50 – 12:15 | Prof. Dr. Lena Burbulla, Investigating key players of neurodegenerative diseases using human disease modeling, Ludwig-Maximilians University Munich, DE |
| 12:15 – 12:40 | Prof. Dr. Edward Fon, Using functional genomics and iPSC models to understand the biology of Parkinson’s disease. McGill University, CA |
| 12:40 – 13:40 | Walking lunch with exhibition and poster session |
| Session 3: Therapeutic innovations for Precision Medicine in PD | Chair: Dr. Frank Hertel, Centre Hospitalier de Luxembourg |
| 13:40 – 14:05 | Prof. Dr. Thomas Gasser, Emerging therapies for genetically defined subgroups of PD, Hertie-Institute for Clinical Brain Research University of Tübingen, |
| 14:05 – 14:30 | Prof. Dr Andrea Kühn, New avenues for neuromodulation in PD for improved treatment and disease modification, Charité – Universitätsmedizin Berlin, DE |
| 14:30 – 14:55 | Prof. Dr. Werner Poewe, Targeting alpha-synuclein for disease modification in PD. Medical University in Innsbruck, AT |
| 14:55 – 15:25 | Coffee break with exhibition and poster session |
| Session 4: Dissecting the Genetic Architecture of PD | Chair: Dr. Patrick May, University of Luxembourg |
| 15:25 – 15:50 | Prof. Andrew Singleton, The Global Parkinson’s Genetics Program: progress and future. Global Parkinson’s Genetics Program, US |
| 15:50 – 16:15 | Dr. Manu Sharma, From Mendelian genes to polygenic risk scores: Widening the arc to understand disease risk and causality, University Tübingen, DE |
| 16:15 – 16:40 | Prof. Dr. Vincenzo Bonifati, Update on novel genes involved in PD pathogenesis, Erasmus University Rotterdam, NL |
| 16:40 – 17:00 | Closing remarks, Prof. Dr. Rejko Krüger, LIH, LCSB, CHL, LU |
| 17:00 – 18:30 | Networking time with poster session and industry exhibition |
| TIME | PROGRAM 8h00-16h40 |
| 8:00 – 8:45 | Welcome coffee |
| Session 5: Cognition and Precision Prevention in PD | Chair: Prof. Dr. Anja Leist, University of Luxembourg |
| 8:45 – 9:10 | Prof. Dr. Elke Kalbe, Prevention of cognitive decline in people with Parkinson´s disease: A call for action, University Hospital of Cologne, DE |
| 9:10 – 9:35 | Dr. Niels Janssen, Dementia risk reduction: from evidence to implementation. Maastricht University, NL |
| Session 6: Fire presentations | Chair: Dr. Gloria Aguayo, Luxembourg Institute of Health |
| 9:35 – 10:05 | 3 * 5+5 min (young researcher presentation based on abstract selection) |
| 10:05 – 10:35 | Coffee break with exhibition and poster session |
| Session 7: Biomarkers and biological classification of PD | Chair: Prof. Dr. Enrico Glaab, University of Luxembourg |
| 10:35 – 11:00 | Prof. Dr. Joaquim Ferreira, Defining the riddle in order to solve it: there is more than one Parkinson’s disease. University of Lisbon, Laboratory of Clinical Pharmacology and Therapeutics, PT |
| 11:00 – 11:25 | Prof. Dr. Christine Klein, New biological classification of Parkinson’s disease – implications for diagnostics; University of Lübeck, University Hospital Schleswig-Holstein; DE |
| 11:25 – 11:50 | Prof. Dr. Brit Mollenhauer, Update on emerging biomarkes in PD, Paracelsus-Elena Klinik, University Medical Center Göttingen, DE |
| 11:50 – 12:15 | Dr Andreea Monnat, Acting Secretary General of Luxembourg National Research Fund |
| 12:15 – 13:15 | Walking lunch with exhibition and poster session |
| Session 8: Epidemiology and Exposome in PD | Chair: Dr. Brice Appenzeller, Luxembourg Institute of Health |
| 13:15 – 13:40 | Prof. Dr. Pille Taba, Does epidemiology lead to prognostic clues for PD? University of Tartu, ES |
| 13:40 – 14:05 | Prof. Mohammed Salama, Advances in technology used for environmental exposure assessment. American University in Cairo, EG |
| 14:05 – 14:55 | Prof. Dr. Alexis Elbaz, Improving causal inference in epidemiologic studies of Parkinson’s disease. Pitié-Salpêtrière Hospital, INSERM, FR |
| Opening Remarks to the next sessions | |
| 14:55 – 15:10 | Minister Ms. Martine Deprez, Ministry of Health and Social Security in Luxembourg |
| Special session: | Chair: Prof. Dr. Jochen Klucken, International cohorts for Precision Medicine in Parkinson’s disease, University of Luxembourg |
| 15:10 – 15:35 | Dr. Kenneth Marek, Parkinson Progression Marker Initiative (PPMI) – Driving biologic definition and Neuronal Synuclein Disease staging to accelerate therapeutic development for PD and related synucleinopathies. Institute for Neurodegenerative Disorders, US |
| 15:35 – 16:00 | Prof. Asha Kishore, Clinical phenotypes and risk factors for Parkinson’s disease in India, Aster Medcity, Kochi, IN |
| 16:00 – 16:25 | Prof. Dr. Nobutaka Hattori, Innovations from molecular phenotyping of Parkinson’s disease for diagnosis and treatment, Juntendo University, RIKEN, JP |
| 16:25 – 16:40 | Closing remarks |
